📣 VC round data is live. Check it out!

Sinopep Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sinopep and similar public comparables like Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen and more.

Sinopep Overview

About Sinopep

Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.


Founded

2009

HQ

China

Employees

N/A

Financials (FY)

Revenue: $287M
EBITDA: $110M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sinopep Financials

Sinopep reported last fiscal year revenue of $287M and EBITDA of $110M.

In the same fiscal year, Sinopep generated $180M in gross profit, $110M in EBITDA, and $49M in net income.

Revenue (LTM)


Sinopep P&L

In the most recent fiscal year, Sinopep reported revenue of $287M and EBITDA of $110M.

Sinopep is profitable as of last fiscal year, with gross margin of 63%, EBITDA margin of 38%, and net margin of 17%.

See analyst estimates for Sinopep
Last FY202320242025202620272028
Revenue$287M$153M$240M$287M
Gross Profit$180M$93M$163M$180M
Gross Margin63%61%68%63%
EBITDA$110M$48M$101M$110M
EBITDA Margin38%31%42%38%
EBIT Margin28%22%32%28%
Net Profit$49M$24M$60M$49M
Net Margin17%16%25%17%
Net Debt$211M---

Financial data powered by Morningstar, Inc.

Sinopep Stock Performance

Sinopep has current market cap of $1B, and enterprise value of $2B.

Market Cap Evolution


Sinopep's stock price is $4.37.

Sinopep share price decreased by 0.7% in the last 30 days, and by 19.2% in the last year.

Sinopep has an EPS (earnings per share) of $0.16.

See more trading valuation data for Sinopep
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$1B-1.6%-0.7%2.5%-19.2%$0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sinopep Valuation Multiples

Sinopep trades at 5.7x EV/Revenue multiple, and 14.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Sinopep

EV / Revenue (LTM)


Sinopep Financial Valuation Multiples

As of June 4, 2026, Sinopep has market cap of $1B and EV of $2B.

Sinopep has a P/E ratio of 28.1x.

Last FY202320242025202620272028
EV/Revenue5.7x10.8x6.8x5.7x
EV/EBITDA14.9x34.2x16.3x14.9x
EV/EBIT20.1x47.9x21.2x20.1x
EV/Gross Profit9.1x17.6x10.1x9.1x
P/E28.1x57.3x23.1x28.1x
EV/FCF(16.2x)(35.8x)(16.1x)(16.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sinopep Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sinopep Margins & Growth Rates

In the most recent fiscal year, Sinopep reported gross margin of 63%, EBITDA margin of 38%, and net margin of 17%.

See estimated margins and future growth rates for Sinopep

Sinopep Margins

Last FY20242025202720282029
Gross Margin63%68%63%
EBITDA Margin38%42%38%
EBIT Margin28%32%28%
Net Margin17%25%17%
FCF Margin(35%)(42%)(35%)

Sinopep Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth57%20%
Gross Profit Growth75%11%
EBITDA Growth110%9%
EBIT Growth126%5%
Net Profit Growth148%(18%)
FCF Growth122%(1%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Sinopep Operational KPIs

Access forward-looking KPIs for Sinopep
Last FY202320242025202620272028
S&M Expenses to Revenue3%4%2%3%
G&A Expenses to Revenue5%7%7%5%
R&D Expenses to Revenue13%12%14%13%
Opex to Revenue34%39%35%34%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sinopep Competitors

Sinopep competitors include Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen, Immatics, Uniphar, ArriVent BioPharma, Ardelyx, Celltrion Pharm and Septerna.

Most Sinopep public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Semnur Pharmaceuticals----
Inhibrx Biosciences1072.6x1855.4x(11.1x)-
Idorsia10.5x10.3x(50.7x)(35.9x)
Precigen146.1x24.3x(12.7x)(20.8x)
Immatics15.3x17.0x(4.4x)(3.7x)
Uniphar0.5x0.5x11.6x11.1x
ArriVent BioPharma--(6.0x)(5.9x)
Ardelyx3.3x2.9x(45.7x)(107.1x)

This data is available for Pro users. Sign up to see all Sinopep competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sinopep

When was Sinopep founded?Sinopep was founded in 2009.
Where is Sinopep headquartered?Sinopep is headquartered in China.
Is Sinopep publicly listed?Yes, Sinopep is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Sinopep?Sinopep trades under 688076 ticker.
When did Sinopep go public?Sinopep went public in 2021.
Who are competitors of Sinopep?Sinopep main competitors include Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen, Immatics, Uniphar, ArriVent BioPharma, Ardelyx, Celltrion Pharm, Septerna.
What is the current market cap of Sinopep?Sinopep's current market cap is $1B.
What is the current revenue of Sinopep?Sinopep's last fiscal year revenue is $287M.
What is the current EV/Revenue multiple of Sinopep?Current revenue multiple of Sinopep is 5.7x.
Is Sinopep profitable?No, Sinopep is not profitable.
How many companies Sinopep has acquired to date?Sinopep hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sinopep has invested to date?Sinopep hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sinopep

Lists including Sinopep

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial